Protective Functions of ZO-2/Tjp2 Expressed in Hepatocytes and Cholangiocytes Against Liver Injury and Cholestasis

Gastroenterology. 2021 May;160(6):2103-2118. doi: 10.1053/j.gastro.2021.01.027. Epub 2021 Jan 16.

Abstract

Background & aims: Liver tight junctions (TJs) establish tissue barriers that isolate bile from the blood circulation. TJP2/ZO-2-inactivating mutations cause progressive cholestatic liver disease in humans. Because the underlying mechanisms remain elusive, we characterized mice with liver-specific inactivation of Tjp2.

Methods: Tjp2 was deleted in hepatocytes, cholangiocytes, or both. Effects on the liver were assessed by biochemical analyses of plasma, liver, and bile and by electron microscopy, histology, and immunostaining. TJ barrier permeability was evaluated using fluorescein isothiocyanate-dextran (4 kDa). Cholic acid (CA) diet was used to assess susceptibility to liver injury.

Results: Liver-specific deletion of Tjp2 resulted in lower Cldn1 protein levels, minor changes to the TJ, dilated canaliculi, lower microvilli density, and aberrant radixin and bile salt export pump (BSEP) distribution, without an overt increase in TJ permeability. Hepatic Tjp2-defcient mice presented with mild progressive cholestasis with lower expression levels of bile acid transporter Abcb11/Bsep and detoxification enzyme Cyp2b10. A CA diet tolerated by control mice caused severe cholestasis and liver necrosis in Tjp2-deficient animals. 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene ameliorated CA-induced injury by enhancing Cyp2b10 expression, and ursodeoxycholic acid provided partial improvement. Inactivating Tjp2 separately in hepatocytes or cholangiocytes showed only mild CA-induced liver injury.

Conclusion: Tjp2 is required for normal cortical distribution of radixin, canalicular volume regulation, and microvilli density. Its inactivation deregulated expression of Cldn1 and key bile acid transporters and detoxification enzymes. The mice provide a novel animal model for cholestatic liver disease caused by TJP2-inactivating mutations in humans.

Keywords: Bile-Blood Barrier; Constitutive Androstane Receptor; Human Disease; Tight Junction Protein-2; Zonula Occludens-2.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 11 / genetics
  • ATP Binding Cassette Transporter, Subfamily B, Member 11 / metabolism
  • Animals
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Bile Acids and Salts / metabolism
  • Bile Canaliculi / metabolism*
  • Bile Canaliculi / pathology
  • Chemical and Drug Induced Liver Injury / drug therapy
  • Chemical and Drug Induced Liver Injury / genetics*
  • Cholagogues and Choleretics / therapeutic use
  • Cholestasis / genetics*
  • Cholic Acid
  • Claudin-1 / metabolism
  • Cytochrome P450 Family 2 / metabolism
  • Cytoskeletal Proteins / metabolism
  • Epithelial Cells
  • Female
  • Fibrosis
  • Genetic Predisposition to Disease
  • Hepatocytes
  • Male
  • Membrane Proteins / metabolism
  • Mice
  • Mice, Knockout
  • Mutation
  • Oxazoles / therapeutic use
  • Permeability
  • Protective Factors
  • RNA, Messenger / metabolism
  • Steroid Hydroxylases / metabolism
  • Tight Junctions / metabolism*
  • Tight Junctions / ultrastructure
  • Ursodeoxycholic Acid / therapeutic use
  • Zonula Occludens-2 Protein / deficiency
  • Zonula Occludens-2 Protein / genetics*

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 11
  • Abcb11 protein, mouse
  • Bile Acids and Salts
  • Cholagogues and Choleretics
  • Claudin-1
  • Cldn1 protein, mouse
  • Cytoskeletal Proteins
  • Membrane Proteins
  • Oxazoles
  • RNA, Messenger
  • Tjp2 protein, mouse
  • Zonula Occludens-2 Protein
  • radixin
  • POPOP
  • Ursodeoxycholic Acid
  • Steroid Hydroxylases
  • Aryl Hydrocarbon Hydroxylases
  • Cyp2b10 protein, mouse
  • Cytochrome P450 Family 2
  • Cholic Acid